Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results…
Pfizer Reports Positive Phase 2 Results for Trispecific Antibody in Moderate-to-Severe Atopic Dermatitis Pfizer Inc. today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults…
Enhertu receives U.S. Priority Review as a post-neoadjuvant therapy for patients with early-stage HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted…
AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from…
Novo Nordisk broadens U.S. patient access to FDA-approved semaglutide treatments through Hims & Hers following a strategic shift in its U.S. GLP-1 business approach. Novo Nordisk today announced it has…
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed or Refractory Multiple Myeloma Halozyme Therapeutics has announced that Johnson & Johnson has received approval from the U.S. Food…
Celltrion Plans Cancellation of 9.11 Million Treasury Shares to Strengthen Shareholder Value Amid Market Volatility Celltrion has announced a significant corporate governance and capital management initiative aimed at strengthening shareholder…
European Commission Approves Zynyz® (retifanlimab) as a First-Line Treatment for Patients with Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Incyte has announced that the European Commission has granted…
NEJM Publishes Phase III ALLEGORY Results Showing Gazyva Reduces Disease Activity in Common Lupus Genentech, a member of the Roche Group, has announced that detailed results from the Phase III…
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase…
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal…
